A study by Dong et al52 demonstrated that KRAS or TP53 mutations were statistically significantly associated with an increased clinical benefit of immunotherapy in NSCLC, but these findings were not confirmed in later studies.53,54 In our study, we used the largest data series to date, to our knowledge, and found that the differences between the DCB group and the NDB group were not statistically significant when the patients were stratified by TP53 or KRAS status. The gene discussed is TP53; the disease is non-small cell lung carcinoma.